COVID-19 高风险美国原住民患者接受或未接受单克隆抗体治疗的结果比较。
Outcome Comparison of High-Risk Native American Patients Who Did or Did Not Receive Monoclonal Antibody Treatment for COVID-19.
机构信息
Whiteriver Indian Hospital, Indian Health Service, Whiteriver, Arizona.
出版信息
JAMA Netw Open. 2021 Sep 1;4(9):e2125866. doi: 10.1001/jamanetworkopen.2021.25866.
Abstract
This quality improvement study compares outcomes among high-risk Native American patients who did or did not receive monoclonal antibody treatment for COVID-19.
摘要
本质量改进研究比较了 COVID-19 高风险的美国原住民患者接受或未接受单克隆抗体治疗的结果。
相似文献
1
Outcome Comparison of High-Risk Native American Patients Who Did or Did Not Receive Monoclonal Antibody Treatment for COVID-19.COVID-19 高风险美国原住民患者接受或未接受单克隆抗体治疗的结果比较。
JAMA Netw Open. 2021 Sep 1;4(9):e2125866. doi: 10.1001/jamanetworkopen.2021.25866.
2
[Not Available].[无可用信息]。
CMAJ. 2021 Jul 5;193(26):E1027-E1028. doi: 10.1503/cmaj.210066-f.
3
Comparison of demographic and clinical characteristics of hospitalized COVID-19 patients with severe/critical illness in the first wave versus the second wave.比较第一波和第二波住院 COVID-19 重症/危重症患者的人口统计学和临床特征。
J Med Virol. 2022 Jan;94(1):291-297. doi: 10.1002/jmv.27319. Epub 2021 Sep 15.
4
Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.巴姆洛单抗和卡西米单抗-伊马维单抗在轻中度 2019 冠状病毒病高危患者中的真实世界临床结局。
J Infect Dis. 2021 Oct 28;224(8):1278-1286. doi: 10.1093/infdis/jiab377.
5
[COVID-19: Still a place for tocilizumab?].[新型冠状病毒肺炎：托珠单抗仍有一席之地？]
Rev Med Interne. 2021 Feb;42(2):73-78. doi: 10.1016/j.revmed.2020.11.016. Epub 2020 Nov 27.
6
Structural Inequalities Established the Architecture for COVID-19 Pandemic Among Native Americans in Arizona: a Geographically Weighted Regression Perspective.结构性不平等为亚利桑那州美洲原住民中的 COVID-19 大流行奠定了基础：基于地理加权回归的视角。
J Racial Ethn Health Disparities. 2022 Feb;9(1):165-175. doi: 10.1007/s40615-020-00940-2. Epub 2021 Jan 19.
7
Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2.托珠单抗治疗感染 SARS-CoV-2 的危重症患者。
Clin Transl Sci. 2021 Nov;14(6):2146-2151. doi: 10.1111/cts.12894. Epub 2021 Oct 27.
8
No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients: Results from a retrospective controlled multicenter study.托珠单抗治疗重症至危重症新型冠状病毒感染患者无效：一项回顾性对照多中心研究结果
Medicine (Baltimore). 2021 May 28;100(21):e26023. doi: 10.1097/MD.0000000000026023.
9
Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.羟氯喹治疗初级保健环境中成人 COVID-19 感染患者（LIBERTY）：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):44. doi: 10.1186/s13063-020-04989-6.
10
Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study.托珠单抗对 COVID-19 住院患者死亡率的影响：一项多中心队列研究。
Clin Microbiol Infect. 2021 Feb;27(2):238-243. doi: 10.1016/j.cmi.2020.09.021. Epub 2020 Sep 23.
引用本文的文献
1
Advancing Health Equity for American Indian and Alaska Native People Through Inclusion in Clinical Trials: Anti-SARS-CoV-2 Monoclonal Antibody Treatment and COVID-19 Outcomes Among Ambulatory Cherokee Nation Health Services Patients.通过纳入临床试验促进美国印第安人和阿拉斯加原住民的健康公平：切诺基民族门诊健康服务患者中抗SARS-CoV-2单克隆抗体治疗与COVID-19结局
Health Equity. 2025 Apr 21;9(1):235-244. doi: 10.1089/heq.2024.0185. eCollection 2025.
2
Recognising the heterogeneity of Indigenous Peoples during the COVID-19 pandemic: a scoping review across Canada, Australia, New Zealand and the USA.认识新冠疫情期间原住民的异质性：对加拿大、澳大利亚、新西兰和美国的一项范围综述
BMJ Public Health. 2024 Dec 30;2(2):e001341. doi: 10.1136/bmjph-2024-001341. eCollection 2024 Dec.
3
Integrated COVID-19 Interventions in a Native American Community: Arizona, December 25, 2021-January 31, 2022.美国亚利桑那州一个原住民社区的 COVID-19 综合干预措施：2021 年 12 月 25 日至 2022 年 1 月 31 日。
Am J Public Health. 2023 Oct;113(10):1089-1092. doi: 10.2105/AJPH.2023.307364. Epub 2023 Jul 27.
4
Real-world effectiveness of casirivimab and imdevimab among patients diagnosed with COVID-19 in the ambulatory setting: a retrospective cohort study using a large claims database.在门诊环境中诊断为 COVID-19 的患者中使用 casirivimab 和 imdevimab 的真实世界疗效：使用大型索赔数据库的回顾性队列研究。
BMJ Open. 2022 Dec 19;12(12):e064953. doi: 10.1136/bmjopen-2022-064953.
5
Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19.皮下注射卡西瑞维单抗和英夫西单抗治疗门诊COVID-19患者的疗效
Infect Dis Ther. 2022 Dec;11(6):2125-2139. doi: 10.1007/s40121-022-00691-z. Epub 2022 Oct 1.
6
In-Hospital Mortality Disparities Among American Indian and Alaska Native, Black, and White Patients With COVID-19.美国印第安人和阿拉斯加原住民、黑人和白人 COVID-19 患者的住院死亡率差异。
JAMA Netw Open. 2022 Mar 1;5(3):e224822. doi: 10.1001/jamanetworkopen.2022.4822.
本文引用的文献
1
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.巴尼韦单抗单药或联合埃特司韦单抗治疗轻中度 COVID-19 患者对病毒载量的影响：一项随机临床试验。
JAMA. 2021 Feb 16;325(7):632-644. doi: 10.1001/jama.2021.0202.
2
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.REGN-COV2，一种中和抗体鸡尾酒疗法，用于治疗门诊新冠患者。
N Engl J Med. 2021 Jan 21;384(3):238-251. doi: 10.1056/NEJMoa2035002. Epub 2020 Dec 17.
3
COVID-19 Mortality Among American Indian and Alaska Native Persons - 14 States, January-June 2020.美国印第安人和阿拉斯加原住民中 COVID-19 的死亡率 - 14 个州，2020 年 1 月至 6 月。
MMWR Morb Mortal Wkly Rep. 2020 Dec 11;69(49):1853-1856. doi: 10.15585/mmwr.mm6949a3.
4
Infectious disease mortality among American Indians and Alaska Natives, 1999-2009.1999-2009 年美国印第安人和阿拉斯加原住民的传染病死亡率。
Am J Public Health. 2014 Jun;104 Suppl 3(Suppl 3):S446-52. doi: 10.2105/AJPH.2013.301721. Epub 2014 Apr 22.
Zotero 插件